Published in Gastroenterology on December 01, 1999
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43
Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut (2000) 2.17
Review article: multiple myeloma and inflammatory bowel disease. Dig Dis Sci (2007) 1.64
Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut (2005) 1.25
Colorectal cancer risk in Crohn's disease. World J Gastroenterol (2008) 0.99
Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther (2009) 0.96
Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer (2013) 0.95
Management of difficult inflammatory bowel disease: where are we now? World J Gastroenterol (2000) 0.90
Immunoactive cannabinoids: therapeutic prospects for marijuana constituents. Proc Natl Acad Sci U S A (2000) 0.88
Radiation exposure from abdominal imaging studies in patients with intestinal Behçet disease. Gut Liver (2013) 0.83
Murine monoclonal anti-tNF antibody administration has a beneficial effect on inflammatory bowel disease that develops in IL-10 knockout mice. Dig Dis Sci (2002) 0.82
Clinically useful monoclonal antibodies in treatment. J Clin Pathol (2002) 0.82
Administration of infliximab in general practitioners' offices is safe. Clin Rheumatol (2007) 0.78
Leukocytapheresis in ulcerative colitis: a possible alternative to biological therapy? Dig Liver Dis (2009) 0.78
Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag (2007) 0.78
Infliximab treatment for Crohn's disease. Postgrad Med J (2001) 0.77
Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut (2005) 0.76
Medical Therapy of Crohn's Disease. Curr Treat Options Gastroenterol (2005) 0.76
Marine Diterpenoids as Potential Anti-Inflammatory Agents. Mediators Inflamm (2015) 0.75
TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review. World J Gastroenterol (2014) 0.75
Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy. Case Rep Pulmonol (2013) 0.75
Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity (1999) 7.34
Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol (1995) 2.71
IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol (1999) 2.58
An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol (2001) 2.26
Partial purification of a nuclear protein that binds to the CCAAT box of the mouse alpha 1-globin gene. Mol Cell Biol (1986) 2.04
Clinical implications of Barrett's esophagus. Arch Intern Med (1996) 2.04
Risk factors for early postoperative recurrence of Crohn's disease. Gastroenterology (1998) 1.98
Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest (2001) 1.96
Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer (1984) 1.95
A new endoscopic technique for the removal of gastric phytobezoars. Gastrointest Endosc (2000) 1.79
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut (2008) 1.75
Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology (1993) 1.75
Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology (2000) 1.74
Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology (2001) 1.69
Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology (2001) 1.63
Identification of sequences within the murine granulocyte-macrophage colony-stimulating factor mRNA 3'-untranslated region that mediate mRNA stabilization induced by mitogen treatment of EL-4 thymoma cells. J Biol Chem (1991) 1.54
Age- and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res (1994) 1.54
Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest (1994) 1.53
Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther (2011) 1.53
Hepatic glutamine synthetase deficiency in fatal hyperammonemia after lung transplantation. Ann Intern Med (1997) 1.50
Successful use of alternate waste nitrogen agents and hemodialysis in a patient with hyperammonemic coma after heart-lung transplantation. Arch Neurol (1999) 1.48
Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr (1995) 1.48
Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther (2014) 1.43
Hepatic scintigraphy in the evaluation of solitary solid liver masses. J Nucl Med (1993) 1.40
Thoracic spine spasms secondary to hemorrhagic intestinal ulcer. Pain Physician (2001) 1.38
Scintigraphic evaluation of liver masses: cavernous hepatic hemangioma. J Nucl Med (1993) 1.38
A common protein binds to two silencers 5' to the human beta-globin gene. Nucleic Acids Res (1989) 1.36
Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1996) 1.35
Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology (1999) 1.35
Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient. Am J Gastroenterol (2001) 1.34
MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther (2007) 1.28
DNA affinity labeling of adenovirus type 2 upstream promoter sequence-binding factors identifies two distinct proteins. Mol Cell Biol (1988) 1.27
Nucleosome disruption precedes transcription and is largely limited to the transcribed domain of globin genes in murine erythroleukemia cells. J Mol Biol (1985) 1.24
Lessons from genetically engineered animal models XI. Novel mouse models to study pathogenic mechanisms of Crohn's disease. Am J Physiol Gastrointest Liver Physiol (2000) 1.22
A new strategy in design of +RNA virus infectious clones enabling their stable propagation in E. coli. Virology (2001) 1.22
Binding of sequence-specific proteins to the adenosine- plus uridine-rich sequences of the murine granulocyte/macrophage colony-stimulating factor mRNA. Proc Natl Acad Sci U S A (1992) 1.21
Abdominal lymphangioma masquerading as a pancreatic cystic neoplasm. J Clin Gastroenterol (1995) 1.20
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer (2006) 1.20
Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol (2001) 1.19
Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am (1999) 1.19
Lack of correlation between natural killer activity and tumor growth control in nude mice with different immune defects. Cancer Res (1984) 1.15
Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. Gastroenterology (1998) 1.10
Schilder's disease. Sex-linked recessive transmission with specific adrenal changes. Arch Neurol (1972) 1.05
Pouchitis associated with primary cytomegalovirus infection. Am J Gastroenterol (1998) 1.03
Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology (2000) 1.03
Delayed leaks and fistulas after esophagogastrectomy: radiologic evaluation. AJR Am J Roentgenol (1993) 1.01
Clinical-pathologic study of early breast cancer treated by primary radiation therapy. J Clin Oncol (1983) 1.01
Ileal carcinoid tumors stimulating Crohn's disease: incidence among 176 consecutive cases of ileal carcinoid. Am J Gastroenterol (1997) 0.99
Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am (1999) 0.99
Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther (2007) 0.99
A 'minimal' approach in design of flavivirus infectious DNA. Virus Res (2001) 0.98
Identification and characterization of a novel transcription factor participating in the expression of eukaryotic initiation factor 2 alpha. J Biol Chem (1989) 0.98
Post-transcriptional regulation of granulocyte-macrophage colony-stimulating factor synthesis in murine T cells. J Immunol (1990) 0.98
Liver biopsy complications and routine ultrasound. Am J Gastroenterol (1996) 0.98
Isolation and characterization of the promoter and flanking regions of the gene encoding the human protein-synthesis-initiation factor 2 alpha. Gene (1989) 0.97
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol (2008) 0.97
A bone morphogenetic protein subfamily: chromosomal localization of human genes for BMP5, BMP6, and BMP7. Genomics (1992) 0.97
ZBP-89, Sp1, and nuclear factor-kappa B regulate epithelial neutrophil-activating peptide-78 gene expression in Caco-2 human colonic epithelial cells. J Biol Chem (2001) 0.96
Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig Dis Sci (1997) 0.96
GI manifestations of Ehlers-Danlos syndrome. Am J Gastroenterol (1996) 0.95
Oxidative enzymes in spinal motor neurons in Werdnig-Hoffmann disease. A comparison with the axonal reaction. Neurology (1966) 0.95
HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS (1999) 0.95
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol (2009) 0.95
Nucleotide regulation and characteristics of potassium channel opener binding to skeletal muscle membranes. Mol Pharmacol (1997) 0.94
Case report 377: Intraosseous lipoma (angiolipoma) of right third rib. Skeletal Radiol (1986) 0.93
Concentrations of calcitonin and catecholamines in pheochromocytomas, a mucosal neuroma and medullary thyroid carcinoma. J Clin Endocrinol Metab (1973) 0.92
Retroperitoneal leiomyosarcoma and gastroparesis: a new association and review of tumor-associated intestinal pseudo-obstruction. Am J Gastroenterol (1995) 0.92
Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease. Aliment Pharmacol Ther (2008) 0.91
The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy. Ann Surg (1985) 0.91
Causes of failure among cuspal-coverage amalgam restorations: a clinical survey. J Am Dent Assoc (2000) 0.90
Resistance to fracture of teeth with various preparations for amalgam. J Dent (1996) 0.89
Radiation-induced changes in the breast. Hum Pathol (1984) 0.88
Detection of interleukin 1 alpha and 1 beta in rabbit tissues during endotoxemia using sensitive radioimmunoassays. J Appl Physiol (1985) (1991) 0.87
Increased expression of interleukin-8 mRNA in ulcerative colitis and Crohn's disease mucosa and epithelial cells. Inflamm Bowel Dis (1995) 0.87
Tregs are dysfunctional in vivo in a spontaneous murine model of Crohn's disease. Mucosal Immunol (2012) 0.87
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer (2012) 0.86
Observations of cortical nodules in human adrenal glands. Their relationship to neoplasia. Cancer (1966) 0.86
A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc (1995) 0.86
Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial. Aliment Pharmacol Ther (1995) 0.86
The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients. Inflamm Bowel Dis (2001) 0.86
Ischemic colitis associated with decongestant use. Ann Intern Med (2000) 0.86
Regulation of eukaryotic translation initiation factor expression during T-cell activation. Biochim Biophys Acta (1993) 0.85
IL-1 alpha induces granulocyte-macrophage colony-stimulating factor gene expression in murine B lymphocyte cell lines via mRNA stabilization. J Immunol (1991) 0.85
The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contractions in rabbit aorta. Biochem Biophys Res Commun (1992) 0.85
Altered renal and platelet arachidonic acid metabolism in cirrhosis. Gastroenterology (1986) 0.85
Calcitonin gene-related peptide and substance P decrease in the rabbit colon during colitis. A time study. Gastroenterology (1991) 0.84
Nutrition and ulcerative colitis. Baillieres Clin Gastroenterol (1997) 0.84
Cytomegalovirus infection as a cause of ileoanal pouchitis. Dis Colon Rectum (2000) 0.84
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. Ann Oncol (2006) 0.84
Vascular A10 cell membranes contain an endothelin metabolizing neutral endopeptidase. Biochem Biophys Res Commun (1991) 0.84
Cancer in inflammatory bowel disease. Med Clin North Am (1994) 0.83
Effects of 16,16-dimethyl prostaglandin E2 and indomethacin on leukotriene B4 and inflammation in rabbit colitis. Prostaglandins (1988) 0.83
Potent inhibition of gastric acid secretion by intravenous interleukin-1 beta and -1 alpha in rats. Peptides (1992) 0.83
Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites. Gastroenterology (1988) 0.83
Helicobacter pylori gastritis: radiographic findings. Radiology (1995) 0.82
Recombinant interleukin 10 for the treatment of active Crohn's disease: lessons in biologic therapy. Gastroenterology (2000) 0.82
Role of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies? Gut (2006) 0.82